Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 28,000 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 28,000 shares of the company’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total value of $807,800.00. Following the sale, the chief financial officer directly owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. This represents a 17.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Thursday, May 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $20.42, for a total value of $187,864.00.
• On Tuesday, April 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.00, for a total transaction of $211,600.00.

Bicara Therapeutics Stock Down 2.6%

Shares of Bicara Therapeutics stock traded down $0.77 during trading on Friday, hitting $28.91. The stock had a trading volume of 584,437 shares, compared to its average volume of 609,333. Bicara Therapeutics Inc. has a 1 year low of $9.47 and a 1 year high of $30.99. The stock has a 50 day simple moving average of $23.27 and a 200 day simple moving average of $20.04. The company has a market capitalization of $1.90 billion, a PE ratio of -10.40 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, equities analysts expect that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently made changes to their positions in BCAX. Siren L.L.C. increased its holdings in Bicara Therapeutics by 11.2% in the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after buying an additional 586,001 shares during the last quarter. Vestal Point Capital LP lifted its stake in Bicara Therapeutics by 2.0% in the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after acquiring an additional 100,000 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Bicara Therapeutics by 26.2% in the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after acquiring an additional 692,933 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its position in Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Bicara Therapeutics by 9.8% in the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after acquiring an additional 195,667 shares in the last quarter.

Analyst Upgrades and Downgrades

BCAX has been the topic of a number of research reports. The Goldman Sachs Group upped their target price on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. HC Wainwright boosted their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Morgan Stanley increased their target price on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Finally, Guggenheim started coverage on shares of Bicara Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $42.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $30.27.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.